Compare OPRA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRA | XNCR |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2018 | 2013 |
| Metric | OPRA | XNCR |
|---|---|---|
| Price | $14.14 | $12.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $23.50 | $22.78 |
| AVG Volume (30 Days) | 637.2K | ★ 795.1K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $583,449,000.00 | $150,132,000.00 |
| Revenue This Year | $27.78 | $18.68 |
| Revenue Next Year | $14.95 | N/A |
| P/E Ratio | $15.67 | ★ N/A |
| Revenue Growth | 30.29 | ★ 38.16 |
| 52 Week Low | $12.62 | $6.92 |
| 52 Week High | $22.50 | $21.00 |
| Indicator | OPRA | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 33.77 |
| Support Level | $13.13 | $13.77 |
| Resistance Level | $14.77 | $15.40 |
| Average True Range (ATR) | 0.48 | 0.79 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 47.09 | 0.00 |
Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.